| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Coactivator 1
(PGC-1): Transcriptional Coactivator and Metabolic Regulator
Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115
Correspondence: Address all correspondence and requests for reprints to: Dr. Bruce M. Spiegelman, Dana-Farber Cancer Institute, One Jimmy Fund Way, Smith Building, Room 958, Boston, Massachusetts 02115. E-mail: bruce_spiegelman{at}dfci.harvard.edu
 |
Abstract |
|---|
 Top Abstract I. IntroductionII. PGC-1{alpha} Regulates...III. Molecular Mechanisms of...IV. Concluding Remarks and...References |
|---|
coactivator 1
(PGC-1). Key cellular signals that control energy and nutrient homeostasis, such as cAMP and cytokine pathways, strongly activate PGC-1. Once PGC-1 is activated, it powerfully induces and coordinates gene expression that stimulates mitochondrial oxidative metabolism in brown fat, fiber-type switching in skeletal muscle, and multiple aspects of the fasted response in liver. The regulation of these metabolic and cell fate decisions by PGC-1 is achieved through specific interaction with a variety of transcription factors such as nuclear hormone receptors, nuclear respiratory factors, and muscle-specific transcription factors. PGC-1 therefore constitutes one of the first and clearest examples in which biological programs are chiefly regulated by a transcriptional coactivator in response to environmental stimuli. Finally, PGC-1’s control of energy homeostasis suggests that it could be a target for antiobesity or diabetes drugs.
Regulates Biological Programs Linked to Energy Homeostasis
and adaptive thermogenesis and heart development and fuel homeostasis: glucose uptake and gluconeogenesis Function
/transcription factor interactions recruits other histone acetyl transferase (HAT)-containing coactivator proteins with RNA processing complexes by p38 MAPK functions in gene expression |
I. Introduction |
|---|
|
TopAbstractI. IntroductionII. PGC-1{alpha} Regulates...III. Molecular Mechanisms of...IV. Concluding Remarks and...References |
|---|
Coactivators usually exist and function as multiprotein complexes. These complexes contain individual proteins that mediate docking on transcription factors and others that mediate functions necessary for transcription itself. These include modifications of histones by acetyltransferase activity, modification of histones by phosphorylation or methylation, and the unwinding and remodeling of chromatin in an ATP-dependent fashion. It is also highly likely that additional enzymatic activities associated with coactivator complexes will be discovered.
The last 20 yr have seen tremendous progress in our understanding of the role of transcriptional control in almost every area of biology—development, physiology, and disease. In the vast majority of cases described to date, a key regulatory step is an alteration in the amount or activity of the transcription factor. However, recent work has shown that biological regulation can also be achieved through modulation of other components of the transcriptional apparatus. The first example of biological regulation at the coactivator level was the demonstration of the key function of a B cell-selective coactivator of the Oct family of transcription factors, Oca-B. Our studies of the regulation of the adipose cell lineage, especially in the divergence of the white vs. brown fat pathways, led us to discover a coactivator with an amazing degree of regulation in different tissues and physiological states. Peroxisome proliferator-activated receptor (PPAR)- coactivator 1 (PGC-1), the subject of this review, is involved in multiple biological responses related to energy homeostasis, thermal regulation, and glucose metabolism.
|
II. PGC-1 Regulates Biological Programs Linked to Energy Homeostasis
|
|---|
|
TopAbstractI. IntroductionII. PGC-1{alpha} Regulates...III. Molecular Mechanisms of...IV. Concluding Remarks and...References |
|---|
and adaptive thermogenesisMost adaptive thermogenesis in small mammals takes place in brown adipose tissue (BAT). BAT is morphologically and metabolically different from white adipose tissue (WAT) and plays an opposite physiological function: dissipation vs. storage of energy. Brown adipocytes contain multiple small droplets of triglycerides and a high number of mitochondria. In addition, their mitochondria contain a specific uncoupling protein-1 (UCP-1), which is expressed only in brown adipocytes. Genetic studies from mice lacking UCP-1 indicate that it is an essential component for cold-induced thermogenesis; however, it seems to play a smaller role for diet-induced thermogenesis (4). Adaptive thermogenesis in BAT is achieved through two main inputs: adrenergic stimulation (5, 6) and thyroid hormone action (7, 8).
Another tissue involved in adaptive thermogenesis is skeletal muscle, particularly in large adult mammals in which there is relatively little brown fat (9, 10). Skeletal muscle represents about 40% of the total body mass and has high oxidative metabolism linked to a high mitochondrial number (11).
Once it was appreciated that the molecular mechanism for brown fat thermogenesis is through uncoupling respiration depending on UCP-1, it was reasonable to speculate that other tissues, such as muscle or liver, might use similar systems to generate heat. By searching for genes similar to UCP-1 in tissues other than brown fat, several groups cloned UCP-2 (12, 13) and UCP-3 (14, 15, 16). Genetic loss-of-function mice have been created that lack UCP-2 or UCP-3 (17). These data support the idea that these proteins participate in uncoupling respiration in mitochondria. However, these mice did not have any alteration in thermogenic function or systemic energy balance. Rather, UCP-2 has been shown to be important in free radical production, defense against infection (18), and insulin secretion in the pancreas (19).
2. PGC-1 regulates components of adaptive thermogenesis and mitochondrial biogenesis.
a. Identification of PGC-1.
Although some of the effectors for adaptive thermogenesis, such as UCP-1, have been extensively studied, relatively little is known about the transcriptional regulation of this process. One useful approach to this problem has been the analysis of the specific brown fat-specific enhancer of UCP-1. UCP-1 gene expression is highly cold inducible through the activation of the sympathetic nervous system and is mediated by ß-adrenoreceptors and cAMP (20, 21). In addition, several activated nuclear hormone receptors play an important role in the differentiation of brown fat cells and in UCP-1 gene expression, including thyroid hormone receptor (TR), retinoic acid receptor (RAR; Ref. 22), and PPARs (PPAR, PPAR; Refs. 23 and 24). The potential involvement of PPAR in this regulation is particularly interesting because of its key role in white fat-specific gene expression and differentiation. Activation of PPAR by synthetic ligands, the antidiabetic thiazolidinediones, has been shown to promote the differentiation of brown fat precursor cells and to cause a hypertrophy of BAT when given to rats (25, 26). Furthermore, PPAR knockout animals lack brown adipose tissue, indicating that it is required for the formation of this tissue, as well as white fat (27, 28). Although these data strongly support the importance of PPAR in brown fat differentiation, it is clear that the same factor alone cannot determine whether adipocyte cells are white (energy storage) or brown (energy dissipation). These data suggested to us the possibility that a specific cofactor might augment and alter PPAR function in brown fat cells, resulting in activation of the thermogenic genes that characterize this cell type. Based on this hypothesis, we cloned a PPAR-interacting protein that is expressed preferentially in brown fat compared with white fat, in which endogenous levels are very low. We called this factor PGC-1 (29).
b. Adrenergic regulation of PGC-1 in brown fat and muscle.
The function of the ß-adrenergic receptors in brown fat and muscle is critical for the response of these tissues to cold and alterations in diet. Physiologically, this stimulation is mediated through the sympathetic nervous system that innervates the brown adipocytes. PGC-1 is strongly induced at the transcriptional level in brown fat and skeletal muscle when mice are exposed to the cold. Consistent with these in vivo data, PGC-1 mRNA is induced in a brown fat cell line treated with a ß-adrenergic receptor agonist, isoproterenol (29). The effect is mediated through the ß3-adrenergic pathway, in that knockout animals for this receptor lack the cold induction of PGC-1 in brown fat (30). In addition, injection of specific ß3-agonists can specifically induce PGC-1 in brown fat (31). Although much less is known about PGC-1ß, a close homolog of PGC-1, it is expressed in brown fat but is not induced upon cold exposure (32).
Interestingly, the adrenergic induction of UCP-1 has been studied in detail, but the transcription factors involved remained unknown. As stated above, PGC-1 strongly coactivates several nuclear receptors that bind to the UCP-1 enhancer. Thus, a likely model is that a major portion of the cAMP effect is mediated via the induction of PGC-1 and subsequent interaction of this factor with nuclear hormone receptors PPAR, PPAR, RAR, and TR. In interesting genetic studies, Kozak (33) has found quantitative trait loci in mice linked to specific chromosomes that regulate both PGC-1 and UCP-1 expression and could account for the appearance of brown fat in white fat depots.
c. PGC- 1 and the adipocyte cell fate decision.
A key question is whether PGC-1 is the major switch in the decision to become either white or brown fat cells. Although it has been proven that PPAR is necessary and sufficient to induce white fat differentiation, it is necessary but not sufficient to induce brown fat differentiation (27, 28). Several pieces of data suggested that PGC-1 is likely to be involved in this decision (29). First, PGC-1 is the only protein thus far described that can powerfully activate the UCP-1 enhancer in non-BAT cell lines. Second, when introduced into white fat cells, PGC-1 induces endogenous UCP-1 gene expression and mitochondrial biogenesis, two decisive features of brown fat. Finally, PGC-1 is a downstream target of the adrenergic signaling, which is the key signaling mediator of brown fat differentiation in cell cultures and after cold exposure. Although these correlations are consistent with PGC-1 playing a key role in the adipocyte cell fate decision (Fig. 1
), experiments to date in culture have not expressed PGC-1 levels comparable to those in vivo, and the resulting UCP-1 gene expression is also far below the in vivo levels. Hence, a more definitive proof of the requirement and sufficiency of PGC-1 as the key switch for the decision between brown and white fat cell lineages will require the manipulation of PGC-1 levels in mouse models.
|
regulates respiration, mitochondrial biogenesis, and gene expression. is highly expressed and inducible by cold or adrenergic stimuli. Exposure to cold temperatures induces mitochondrial proliferation and increased uncoupling of respiration. The role of thyroid hormone in stimulating mitochondrial biogenesis and in the induction of mitochondrial genes encoded in the nucleus is well established (34). Scarpulla and collaborators (35, 36) identified and cloned two novel transcription factors, nuclear respiratory factor (NRF)-1 and -2, that bind to the promoter region of a broad range of mitochondrial genes encoded in the cell nucleus, including ß-ATP synthase, cytochrome-c, cytochrome-c-oxidase subunit IV, and mitochondrial transcription factor A (mtTFA). It is of particular interest that the NRFs turn on mtTFA, a key transcriptional activator that translocates to the mitochondria and activates mitochondrial DNA replication and transcription.
PGC-1 has a major impact on the NRF system (Fig. 2). When introduced into muscle cells, PGC-1 dramatically induces gene expression for NRF-1, NRF-2, and mtTFA. Furthermore, PGC-1 physically interacts with NRF-1 and coactivates its transcriptional activity (37). A dominant negative allele of NRF-1 completely blocks PGC-1’s ability to induce mitochondrial proliferation, indicating the central role of this transcriptional factor/coactivator pair. Thus, PGC-1 and its functions provide a plausible molecular basis for the connection between environmental/hormonal stimuli and mitochondrial biogenesis and respiration when the organism has altered energy or thermogenic requirements.
|
induces UCP-1 but not UCP-2 or -3 (29). In muscle cells (in which UCP-1 is not expressed), we have shown that expression of PGC-1 also induces uncoupled respiration, but this correlated with increased expression of UCP-2 but not UCP-1 or UCP-3 (37). The transcription factor mediating this cell-specific regulation of UCP-2 in muscle cells is currently unknown. Furthermore, it is not known whether the uncoupling activity observed in either fat or muscle cells expressing PGC-1 is due to UCPs or other molecules involved in the uncoupling of respiration.
The results discussed above were performed in cultured cells, either fat or muscle. Interestingly, two different murine genetic models, one lacking the translation inhibitor of the eukaryotic initiation factor 4E binding protein (38) and the other overexpressing the forkhead transcription factor FOXC2 (39) in fat depots, display white adipose depots that begin to take on the distinctive multilocular appearance of brown adipocytes and express UCP-1. In both types of animals there was a striking correlation between the brown fat phenotype and elevated PGC-1 levels.
B. Cytokines and PGC-1
Cachexia is a chronic state of negative energy balance and muscle wasting that is a severe complication of cancer and prolonged infection. A common feature of cachexia is an elevation in circulating cytokine levels. Elevation in inflammatory cytokines has been shown to be an important feature of cachexia induced by bacteria, HIV, a variety of cancers, and heart failure (40, 41). However, there has been little molecular mechanistic insight as to how cytokines stimulate metabolic rates. These proteins bind membrane receptors and trigger different signaling cascades involving protein kinases such as inhibitor 
B kinase (42) and the stress-activated kinases p38 MAPK and c-Jun N-terminal kinase (43, 44). These enzymes phosphorylate multiple targets, including transcription factors, either in the cytoplasm or in the nucleus and regulate gene transcription.
Given the ability of PGC-1 to activate a broad program of thermogenesis, PGC-1 constitutes a potential candidate for being the target of cytokines in cachexia and energy expenditure (Fig. 2
). Indeed, we have shown that cytokines such as IL-1, IL-1ß, and TNF can activate the transcriptional activity of PGC-1 through direct phosphorylation by p38 MAPK (Section III.E for mechanistic details), resulting in stabilization and activation of PGC-1 protein. Cytokine or lipopolysaccharide induced activation of PGC-1 in muscle cells and muscle in vivo, causing increased respiration and expression of genes linked to mitochondrial uncoupling and energy expenditure (45). This study suggested a possible anticachectic benefit for the inhibition of p38 MAPK or PGC-1 activity in muscle tissue. Future studies in different cachectic murine models must address the precise involvement and/or requirement of PGC-1 in the cachectic response.
C. PGC-1 and heart development
Heart expresses relatively high levels of PGC-1 mRNA. Because this tissue is not noted for being thermogenic, it was particularly interesting to determine the function of this coactivator in the heart. PGC-1 expression is greatly increased in the developing mouse heart, immediately before the large burst of mitochondrial biogenesis and oxidative metabolism that precedes birth (46). Presumably, this burst in oxidative metabolism reflects the large requirement for ATP as the neonate heart requires more energy. When PGC-1 is introduced into cultured cardiac myocytes, increases in both mitochondrial biogenesis and respiration are observed. However, unlike what was seen in fat and muscle cells, most of this respiration was tightly coupled to ATP synthesis. Massive overexpression of PGC-1 in the hearts of mice resulted in a large increase in mitochondrial biogenesis and a dilated cardiac myopathy (46). This myopathy was thought to be due to the gross overexpression of PGC-1.
Cardiac hypertrophy due to pressure overload in mice causes a conversion from fatty acid oxidation to glycolytic metabolism (47). PGC-1 expression decreases dramatically as fatty acid oxidation drops, suggesting that this decrease in oxidative metabolism is secondary to the loss of PGC-1 expression. It will be extremely interesting to determine whether this drop in PGC-1 levels is adaptive or maladaptive.
The specific genes regulated by PGC-1 in cardiac cells include several genes of the electron transport chain, mitochondrial biogenesis, and fatty acid ß-oxidation. The regulation of carnitine O-palmitoyltransferase-1, a key component of ß-oxidation, occurs via docking and coactivation of PGC-1 on PPAR (48). As there are multiple pathophysiological states in which cardiac mitochondrial function is altered, the PGC-1 regulatory pathway could conceivably be a target for the development of novel therapeutic strategies to improve dysfunction in certain cardiac diseases.
D. PGC-1 and fuel homeostasis: glucose uptake and gluconeogenesis
1. PGC-1 and glucose uptake.
The activation of increased energy expenditure ultimately requires an increased uptake and metabolism of fuels. As mentioned above, PGC-1 has been shown to stimulate genes of fatty acid oxidation in cardiac cells, and induction is associated with an increase in fatty acid oxidation in adipocytes and in heart (46, 48). In addition, it was shown that these effects were increased when PPAR was coexpressed. Fatty acid oxidation from 14C-labeled palmitate was also increased in these cells. Whether fatty acid uptake is also augmented in these cells has not been determined.
The effects of PGC-1 on glucose uptake and metabolism is of particular interest in diabetes because there are numerous studies indicating that the rates of mitochondrial oxidation can affect glucose uptake (49). Indeed, simultaneous to the effects of PGC-1 on mitochondrial respiration in skeletal muscle cells, this coactivator also induces gene expression for the insulin-sensitive glucose transporter (Glut-4) and increases glucose uptake (50). The relative insulin sensitivity of this transport process, however, does not increase. This effect on Glut-4 gene expression is partially mediated through PGC-1 binding to and coactivating the muscle transcriptional regulator MEF2 (myocyte enhancer factor-2), probably the MEF2C isoform.
2. PGC-1 and hepatic gluconeogenesis.
Mammals have highly regulated systems to maintain blood glucose levels within tight limits, despite intermittent access to food. The central nervous system and red blood cells are particularly dependent on this substrate. Blood glucose levels are controlled by the hormonal modulation of glucose production and peripheral glucose uptake.
The liver is the major producer of glucose and does this through two different pathways. One is glycogenolysis, or the breakdown of glycogen that occurs in a relatively short-term fast. A second pathway, gluconeogenesis, is turned on with a medium- to long-term fast and involves de novo synthesis of glucose from precursors such as lactate, pyruvate, glycerol, and alanine. The rate of gluconeogenesis is controlled by the activities of three key enzymes: phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,6-bisphosphatase, and glucose-6-phosphatase. Hormonal modulation of these enzymes is mainly controlled at the transcriptional level with insulin, glucagon, and glucocorticoids being key. Gluconeogenesis occurs in fasting or diabetic states in which insulin is low or the liver is insulin resistant. In particular, insulin blocks the actions of the progluconeogenic hormones, glucagon and glucocorticoids. Although the promoters of genes involved in gluconeogenesis, especially PEPCK, have been studied extensively, no transcription factor has been found that is both regulated by the gluconeogenic hormones and has the ability to robustly activate the program of gluconeogenesis.
Our original studies in normal, ad libitum-fed mice had shown very little expression of PGC-1 mRNA in the liver. However, more recent studies illustrate that PGC-1 expression in liver is dramatically increased by fasting (51, 52). Furthermore, PGC-1 is also greatly induced in the liver of streptozotocin-injected mice, a model of type 1, insulin-deficient diabetes. It is also induced in ob/ob mice, a model of type 2 diabetes with high insulin levels but profound insulin resistance. A key role for insulin as a suppressor of PGC-1 expression in liver was shown using mice having liver-specific mutations in the insulin receptor, the LIRKO mouse. PGC-1 was highly elevated in these mice, as well.
In all of these animal models, the expression of PGC-1 correlated well with hepatic gluconeogenesis. We therefore examined the ability of gluconeogenic hormones to activate PGC-1 expression in primary hepatocytes. Glucagon, acting via cAMP, and glucocorticoids are the major positive factors activating the genes of gluconeogenesis in liver. Treatment of hepatocytes with 8-bromo-cAMP, a cell-permeable analog of cAMP, induced mRNA expression of PEPCK and glucose-6-phosphatase, key enzymes of gluconeogenesis. Dexamethasone, a synthetic glucocorticoid, increased PGC-1 gene expression only slightly but markedly synergized with 8-bromo-cAMP in the induction of PGC-1 mRNA (51).
These correlative studies led us to directly test a direct effect for PGC-1 in the activation of gluconeogenesis (Fig. 3). Primary hepatocytes were infected with adenoviruses encoding for the expression of either green fluorescent protein or PGC-1. Remarkably, PGC-1 expression stimulated the expression of mRNA for all three key genes of gluconeogenesis: PEPCK, fructose 1,6-bisphosphatase, and glucose-6-phosphatase. Experiments performed at different doses of virus indicated that maximal induction of these genes occurred at approximately the same levels of PGC-1 protein that are present in fasted liver (51).
|
stimulated a 3-fold increase in the ability of hepatocytes to secrete glucose when provided with gluconeogenic precursors. Although this process was stimulated in control hepatocytes by 8-bromo-cAMP, no further augmentation was observed in the cells expressing PGC-1 via adenovirus, suggesting that a major effect of the hepatic cAMP was the elevation of PGC-1.
Adenoviral-based vectors were also used to modify PGC-1 expression in the liver of rats in vivo (51). Rats were killed 5 d after tail-vein injection of virus expressing PGC-1 or green fluorescent protein. Ad libitum-fed rats that received the PGC-1 virus had an elevation of PGC-1 protein to approximately the levels seen in the fasted state of control animals. The PGC-1 recipient animals also had an elevation in PEPCK and glucose-6-phosphatase mRNA, as well as a significant rise in blood glucose and insulin. These data indicate that PGC-1 can regulate gluconeogenesis in vivo at physiological protein concentrations. cAMP response element binding protein (CREB), a transcription factor activated by glucagon and cAMP, directly activated the expression of PGC-1 through binding to its promoter. Indeed, overexpression of PGC-1 in CREB-deficient mice restored glucose homeostasis and rescued expression of gluconeogenic genes (52).
The PEPCK promoter has been used to study the mechanistic basis for PGC-1’s actions in gluconeogenesis. Utilizing transfections of the wild-type and mutant versions of the PEPCK promoter, coactivation of two nuclear receptors, hepatocyte nuclear factor-4 (HNF-4) and the glucocorticoid receptor, appear to be important (51). The interaction with HNF-4 utilizes the activation function (AF)-2 domain of this receptor and the major LXXLL (amino acids 142–146) of PGC-1. Interestingly, the interaction between LXXLL domain of coactivators and the AF-2 of most receptors is ligand dependent, but PGC-1 can coactivate HNF-4 without any addition of ligands.
In addition, one intriguing question is how insulin acts to suppress PGC-1 expression and whether this action of insulin is direct or via the counterregulatory hormones controlled by insulin: glucagons and the glucocorticoids. There is good evidence for the involvement of the protein kinase acute transforming retrovirus thymoma (AKT2) and Forkhead box protein 01 (FOXO1) transcription factor in the insulin suppression of gluconeogenesis (53, 54). Whether these function directly in PGC-1 gene expression or through other mechanisms remains to be determined.
|
III. Molecular Mechanisms of PGC- 1 Function
|
|---|
|
TopAbstractI. IntroductionII. PGC-1{alpha} Regulates...III. Molecular Mechanisms of...IV. Concluding Remarks and...References |
|---|
is now part of a small family of transcriptional coactivators that includes the close homolog PGC-1ß (32, 55) and PGC-1-related coactivator (Ref. 56 and Fig. 4). All these proteins share a high degree of homology in the N terminus and at the C terminus. The N terminus of all of these proteins contains a transcriptional activation domain and includes the major nuclear hormone receptor-interacting motif (LXXLL). The C-terminal region contains an RNA-binding motif (RMM) and a serine-arginine-rich (RS) domain. Therefore, an unusual feature of the PGC-1 family is the presence of transcriptional activation domains and RNA processing motifs in the same molecule.
|
, that these proteins in cold-blooded animals may be linked to mitochondrial function and/or regulation of other cellular processes related to energy metabolism.
It is important to note that it is not yet clear whether the biological functions described so far for PGC-1 can also be carried out by PGC-1ß or PGC-1-related coactivator. Based on the cellular expression and regulations described (32), it is likely that they will overlap in some of the functions, but other new biological responses might be also expected.
B. Analysis of PGC-1/transcription factor interactions
1. Interaction with different transcription factor families.
Transcriptional coactivators are recruited to particular DNA sequences in gene promoters through direct interaction with transcription factors. PGC-1 was first identified as a protein of 798 amino acids that interacts with the nuclear receptor PPAR, the master regulator of adipocyte differentiation (29). Structure-function analysis of PGC-1 revealed that the N-terminal 200 amino acids contain a potent transcriptional activation domain that is very rich in acidic amino acids (Fig. 4). Embedded in this region is an LXXLL sequence (amino acids 142–146), a motif known to be responsible for ligand-dependent interaction of other coactivators with nuclear hormone receptors (57). The LXXLL motif of PGC-1 belongs to the class III (58) and appears to interact with different amino acids within the AF-2 of the estrogen receptor (ER) compared with steroid receptor coactivator-1 (SRC-1), suggesting that there are structural differences between LXXLL motifs among the different coactivators. The LXXLL motif on PGC-1 is absolutely required for the ligand-dependent interaction with ER (59), PPAR (48), RXR (60), glucocorticoid receptor (GR; Ref. 61), and probably other nuclear hormone receptors. Interestingly, HNF4 also interacts with this motif of PGC-1 without addition of any ligand, suggesting that this nuclear hormone receptor is in an active conformation even without the addition of exogenous ligand (51). PGC-1 also uses different non-LXXLL domains to interact with certain other transcription factors: a domain between amino acids 200 and 400 interacts with PPAR (29) and NRF-1 (37) and a region between amino acids 400 to 500 that interacts with MEF2-C (50). More detailed analyses of these interactions are required to better define these binding domains.
2. PCG-1 coactivates PPAR in a promoter-specific manner.
PGC-1 interacts with several nuclear hormone receptors present in the UCP-1 enhancer. The nature of these interactions can be ligand dependent, as in the case of RAR or TR, or ligand independent as with PPAR (29). When the interaction between PGC-1 and a nuclear receptor is not ligand regulated, PGC-1 appears to interact with the central hinge region of the receptor; when this interaction is ligand dependent, interaction with PGC-1 appears to be with the C-terminal AF-2 region of the receptor.
We have shown that PGC-1 coactivates both PPAR and the thyroid receptor in the UCP-1 enhancer. This activation was clearly synergistic after stimulation of cells with cAMP, a potent inducer of UCP-1 gene expression. If these mechanisms were very simple, one could expect that any coactivator would induce all the target genes of particular nuclear receptors without any promoter specificity. However, because not all promoters of endogenous genes with functional PPAR binding sites are activated by PGC-1, there is apparent promoter specificity even when this coactivator is working through the same nuclear receptor. A good example of this is the selectivity shown with the genes for UCP-1 and adipocyte protein 2 (aP2). Expression of PGC-1 in white fat cells turn on UCP-1 gene expression but failed to activate aP2 gene (29), the first gene actually identified as a target of PPAR (62). This clearly illustrates that transcriptional coactivators are not only boosters of transcription but also play a key role in specification of the gene targeted by a transcription factor. Similar conclusions have been drawn by other investigators using chromatin immunoprecipitation analysis of the ER target genes, showing that in different promoters the ER binds to different coactivators (63). The molecular basis of this phenomena is currently unknown.
C. PGC-1 recruits other histone acetyl transferase (HAT)-containing coactivator proteins
Most coactivators potentiate transcriptional activity by having specific enzymatic functions that are required to remodel chromatin and initiate transcription (64, 65, 66). PGC-1 does not have significant amino acid sequence homology to other transcriptional coactivator families. In addition, PGC-1 does not contain any recognizable HAT domain and does not appear to have this intrinsic enzymatic activity. However, we have shown that the N-terminal activation domain of PGC-1 recruits proteins that contain HAT activity, such as SRC-1 and CREB binding protein (CBP/p300; Ref. 67). In addition, PGC-1 is also present in a complex containing RNA polymerase II. Whether PGC-1 is also part of the TR-associated proteins (TRAP)/vitamin-D receptor interacting proteins/activated recruited cofactor or the brahma-related gene 1/human brahma complexes is unknown.
The model of recruitment of transcriptional coactivators described above portrays the DNA binding transcription factor in a largely passive role, functioning mainly to localize the coactivator complexes to genes that are marked for activation. Conversely, the coactivator complex has been thought to be constitutively active, requiring only proper positioning in the genome to initiate transcription. We have investigated the mechanism of transcriptional activation and a potential role for transcription factor docking to PGC-1. Interestingly, the binding of SRC-1 and CBP/p300 to the N terminus of PGC-1 is dependent upon docking of transcription factors such PPAR and NRF-1 to the amino acids 200–400 region of PGC-1 (67). This suggests that PGC-1 is in a relatively quiescent state when not bound to a transcription factor; however, it becomes highly active when the transcription factor binds and induces a conformation change that recruits SRC-1 and CBP/p300 into the complex. Thus, transcription factor docking switches on the activity of this coactivator protein. Whether this phenomenon of transcriptional activation via a transcription factor docking event is a common feature of coactivators remains to be determined.
D. Interaction of PGC-1 with RNA processing complexes
A large body of evidence has suggested that pre-mRNA splicing is linked to transcription in vivo (68, 69). However, the molecular mechanisms that couple transcription and mRNA processing have not been elucidated. The fact that PGC-1 contains domains involved in splicing and other domains involved in binding to transcriptional factors and other coactivators makes PGC-1 an excellent candidate to study the integration of these two processes.
The C terminus of PGC-1 contains two domains involved in RNA processing: a RS domain at amino acids 565–631 and an RMM domain at amino acids 677–709 (29). As mentioned above, proteins containing paired RNA-binding motifs and RS domains have been shown to interact with the C-terminal domain of RNA polymerase II, indicating a putative link between transcription and RNA processing (70). In fact, we have shown that PGC-1 is in a complex with the phosphorylated form of RNA polymerase II and other factors involved in elongation such as cyclin-dependent kinase 9 and cyclin T. The C-terminal domain of PGC-1 that contains the RS and RMM was responsible for maintaining these interactions (71).
PGC-1 contains two putative nuclear localization signals and localizes to the cell nucleus (amino acids 326–333, 627–633, and 651–667). The localization in the nucleus is not homogenous but is more concentrated in nuclear speckles, typical of splicing factors. This localization to speckles is lost in mutants that lack the RS and RMM domains. Indeed, PGC-1 is in a complex with splicing factors such as splicing component, 35 kDa (SC35); serine/arginine protein, 75 kDa (SRp75); serine/arginine protein, 55 kDa (SRp55); and serine/arginine protein, 40 kDa (SRp40), suggesting that this coactivator can participate in the RNA splicing process. In addition, we have also shown that PGC-1 modulates both expression and processing of a target fibronectin mini-gene (71). Interestingly, PGC-1 does not participate in RNA processing unless it is involved in the transcription of that particular gene. It would be interesting to identify specific RNA targets to which PGC-1 binds and the mechanisms by which processing and/or stabilization functions are controlled.
E. Phosphorylation of PGC-1 by p38 MAPK
It is well established that transcription factors are targets of multiple signal transduction pathways, but there is also emerging evidence that coactivators can also be targets of these signaling pathways in response to growth factors, hormones, and ligands. For example, it has been shown that CBP transcriptional activity is enhanced in response to calcium signaling through calmodulin kinase IV (72). In addition, SRC-1 has been shown to be a target of cAMP signaling through protein kinase A (PKA; Ref. 73). Therefore, regulation of transcriptional coactivator function provides a target to integrate different responses to specific signals across multiple transcription factors.
As discussed in more detail in Section II.B, the role of cytokines in energy expenditure caused us to examine the effects of protein kinases downstream of cytokines on PGC-1 structure and function. We have found that p38 stress-activated MAPK phosphorylates PGC-1 in three residues (T262, S265, and T298; Ref. 45). Indeed, it was shown that phosphorylation of PGC-1 on those residues leads to increased stability and half-life. It is interesting that these phosphorylations occur in a region previously shown to play an important regulatory role in PGC-1 binding to transcription factors. Earlier work (67) has illustrated that this region (amino acids 200–403) mediates a repressive effect in transcription and also serves to dock several transcription factors, including many nuclear receptors and NRF-1. The docking of these transcription factors causes a conformational change that accelerates the binding of other transcriptional effector proteins into this complex, including CBP/p300 and SRC-1 (67). Whether the p38 MAPK-mediated phosphorylations affect transcription factor docking or the recruitment of other coactivator proteins to a PGC-1 complex remains to be determined. Furthermore, how these phospho-amino acids change protein stability is currently under investigation.
Kralli’s group (74) has also shown that activation of p38 MAPK leads to an increase in transcriptional activity of PGC-1. They hypothesize the existence of a putative repressor that binds to the PGC-1 LXXLL motif and that the interaction is released upon activation of p38 MAPK. Interestingly, it has been shown that PPAR/PGC-1 transcriptional activity can be activated through the p38 MAPK pathway, having possible physiological roles in heart stress conditions (75). However, the precise mechanism by which p38 MAPK modification of PGC-1 alters the amount and activity of this coactivator remains to be determined and could have important therapeutic implications.
F. Model of PGC-1 functions in gene expression
How does PGC-1 activate specific gene targets? The N-terminal transcriptional activation domain of PGC-1 and additional regions bind to DNA-binding proteins and recruit proteins with HAT activity, strongly indicating PGC-1’s involvement in transcription initiation on promoters of particular genes. Two conserved protein domains in the C terminus of PGC-1 that have homology to proteins involved in RNA processing, as well as the interaction of PGC-1 with splicing and elongation factors, would also indicate its participation in posttranscriptional initiation processes (Fig. 5). Taken together, three possible models could explain how PGC-1 affects the activation of particular target genes. In some cases, PGC-1 could act as a classical transcriptional activator, binding to specific transcription factors and increasing rates of transcription initiation. In this model, PGC-1 would remain bound to the promoter through the transcription factor. One interesting possibility here is that PGC-1 could also provide some degree of promoter specificity to the transcription factor. In a second model, PGC-1 could affect certain genes not by affecting transcriptional initiation but by targeting RNA processing functions such as elongation, mRNA capping, alternative mRNA splicing, or even mRNA stability. A third model would combine these two models: PGC-1 is a dynamic player involved in several different aspects of gene expression. PGC-1 it would first be loaded at the promoter region through transcription factor docking and recruitment of HAT complexes. Once transcriptional initiation has started, PGC-1 would be involved in the elongation process through interaction with elongation factors and phosphorylated RNA polymerase II, presumably affecting the rates of RNA elongation and/or splicing.
|
|
IV. Concluding Remarks and Future Perspectives |
|---|
|
TopAbstractI. IntroductionII. PGC-1{alpha} Regulates...III. Molecular Mechanisms of...IV. Concluding Remarks and...References |
|---|
is involved in a somewhat bewildering array of disparate biological responses. However, a common theme is that PGC-1 promotes patterns of gene expression that favor oxidative metabolism in various forms. Clearly, brown fat differentiation involves the execution of a program that emphasizes mitochondrial-based fuel oxidation to generate heat. Similarly, the ability of PGC-1 to promote mitochondrial biogenesis and respiration in skeletal muscle indicates an important choice to utilize oxidative, as opposed to glycolytic, metabolism. Interestingly, skeletal muscle has different fiber types that differ greatly in these parameters. Indeed, slow-twitch muscle is composed primarily of type I fibers that are much richer in mitochondria and more dependent on oxidative metabolism. In contrast, fast-twitch muscle contains more type 2b fibers that rely more on glycolitic metabolism. Preliminary data in our laboratory suggest that PGC-1 is expressed at much higher levels in slow-twitch muscle, indicating a possible role in some aspects of fiber-type decisions.
The role of PGC-1 in hepatic glucose output seems quite distinct in that gluconeogenesis is not an oxidative response. However, it must be recalled that gluconeogenesis is just one part of the fasted response in liver, a state that certainly does involve a greatly increased level of ß-oxidation of fatty acids in mitochondria. A role for PGC-1 in this program of ß-oxidation has previously been shown in fat and cardiac cells, and it is highly likely to be true in liver as well. Hence, although it is certainly not a differentiation response per se, it is very likely that PGC-1 plays a role in the physiological switch in liver between the fed and fasted states.
Because of the role of PGC-1 in many important metabolic processes, it is worth asking whether and how the activities of PGC-1 might be modulated for therapeutic purposes. PGC-1’s function in the BAT thermogenic program, regulation of Glut-4 and mitochondrial oxidation in muscle, and the apparently dominant role of PGC-1 in hepatic gluconeogenesis all suggest that this coactivator could be a target for antiobesity or diabetes drugs. Of course, this wide range of physiological actions also points out a problem: activation or inhibition is going to have to be tissue selective or tissue specific to be useful. For example, it is essentially established that drugs that inhibit gluconeogenesis in liver can have a profound antidiabetic action in humans. Hence, an inhibitor of PGC-1 could theoretically ameliorate this disorder. Unfortunately, mitochondrial biogenesis and oxidation, probably influenced and controlled by PGC-1, is critical for the health of heart, skeletal muscle, and many other tissues. This suggests that the usefulness of PGC-1 as a therapeutic target will all come down to an ability to achieve biological specificity.
However, because PGC-1 is a coactivator and is dependent on the docking on particular transcription factors to execute different biological programs, inhibition of different docking events should affect some, but not all, biological responses. The ability of PGC-1 to stimulate gluconeogenesis seems to depend on PGC-1’s physical interaction with HNF-4 and the GR. The activation of mitochondrial biogenesis in skeletal muscle is dependent upon the docking on NRF-1. Thus, targeting specific docking events between PGC-1 and particular transcription factors might offer new theoretical possibilities to control metabolism; where this involves nuclear receptors, as in gluconeogenesis, opportunities might be greater as agonists or antagonists of these receptors with specificity for PGC-1 might be developed.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Abbreviations: AF, Activation function; BAT, brown adipose tissue; CBP, CREB binding protein; CREB, cAMP response element binding protein; ER, estrogen receptor; Glut-4, insulin-sensitive glucose transporter; GR, glucocorticoid receptor; HAT, histone acetyl transferase; HNF-4, hepatocyte nuclear factor-4; MEF2, myocyte enhancer factor-2; mtTFA, mitochondrial transcription factor A; NRF, nuclear respiratory factor; PEPCK, phosphoenolpyruvate carboxykinase; PGC, PPAR- coactivator 1; PKA, protein kinase A; PPAR, peroxisome proliferator-activated receptor; RAR, retinoic acid receptor; RMM, RNA-binding motif; RS, serine-arginine-rich; SRC-1, steroid receptor coactivator-1; TR, thyroid receptor; TRAP, TR-associated protein; UCP, uncoupling protein; WAT, white adipose tissue.
|
References |
|---|
|
TopAbstractI. IntroductionII. PGC-1{alpha} Regulates...III. Molecular Mechanisms of...IV. Concluding Remarks and...References |
|---|
activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem 276:1486–1493. Mol Cell Biol 16:3410–3419[Abstract]
promotes brown adipocyte differentiation. J Biol Chem 271:29909–29914 is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585–595[CrossRef][Medline]
is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611–617[CrossRef][Medline]
coactivator-1. Biochem Biophys Res Commun 261:870–876[CrossRef][Medline]
coactivator 1ß (PGC-1ß), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem 277:1645–1648B. Curr Opin Cell Biol 11:226–232[CrossRef][Medline]
coactivator-1. Mol Cell 8:971–982[CrossRef][Medline]
coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106: 847–856
in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 20:1868–1876. J Biol Chem 277: 13918–13925
2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224–1234 coactivator-1 through transcription factor docking. Science 286:1368–1371. A potential role in the cardia metabolic stress response. J Biol Chem 276:44495–445012-stimulated adipogenesis. Nature 417: 563–567This article has been cited by other articles:
 |
|
 |
|
  Y. Zhang, P. Huypens, A. W. Adamson, J. S. Chang, T. M. Henagan, A. Boudreau, N. R. Lenard, D. Burk, J. Klein, N. Perwitz, et al. Alternative mRNA Splicing Produces a Novel Biologically Active Short Isoform of PGC-1{alpha} J. Biol. Chem., November 20, 2009; 284(47): 32813 - 32826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Won Kang, S. Ribich, B. W. Kim, S. J. Hagen, A. C. Bianco, and D. E. Cohen Mice lacking Pctp /StarD2 exhibit increased adaptive thermogenesis and enlarged mitochondria in brown adipose tissue J. Lipid Res., November 1, 2009; 50(11): 2212 - 2221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Eberlein, A. Takasuga, K. Setoguchi, R. Pfuhl, K. Flisikowski, R. Fries, N. Klopp, R. Furbass, R. Weikard, and C. Kuhn Dissection of Genetic Factors Modulating Fetal Growth in Cattle Indicates a Substantial Role of the Non-SMC Condensin I Complex, Subunit G (NCAPG) Gene Genetics, November 1, 2009; 183(3): 951 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vettor, G. Milan, C. Franzin, M. Sanna, P. De Coppi, R. Rizzuto, and G. Federspil The origin of intermuscular adipose tissue and its pathophysiological implications Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E987 - E998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Theys, T. Bouckenooghe, M.-T. Ahn, C. Remacle, and B. Reusens Maternal low-protein diet alters pancreatic islet mitochondrial function in a sex-specific manner in the adult rat Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1516 - R1525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Rytinki and J. J. Palvimo SUMOylation Attenuates the Function of PGC-1{alpha} J. Biol. Chem., September 18, 2009; 284(38): 26184 - 26193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Wu and Y. Zhang Minireview: Role of Protein Methylation and Demethylation in Nuclear Hormone Signaling Mol. Endocrinol., September 1, 2009; 23(9): 1323 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Huber, J. L. Miles, A. M. Norman, N. M. Thompson, M. Davison, and B. H. Breier Prenatally Induced Changes in Muscle Structure and Metabolic Function Facilitate Exercise-Induced Obesity Prevention Endocrinology, September 1, 2009; 150(9): 4135 - 4144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Kim, Y.-H. You, D.-S. Ham, J.-H. Cho, S.-H. Ko, K.-H. Song, H.-Y. Son, H. Suh-Kim, I.-K. Lee, and K.-H. Yoon Suppression of Peroxisome Proliferator-Activated Receptor {gamma}-Coactivator-1{alpha} Normalizes the Glucolipotoxicity-Induced Decreased BETA2/NeuroD Gene Transcription and Improved Glucose Tolerance in Diabetic Rats Endocrinology, September 1, 2009; 150(9): 4074 - 4083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bugger, D. Chen, C. Riehle, J. Soto, H. A. Theobald, X. X. Hu, B. Ganesan, B. C. Weimer, and E. D. Abel Tissue-Specific Remodeling of the Mitochondrial Proteome in Type 1 Diabetic Akita Mice Diabetes, September 1, 2009; 58(9): 1986 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, et al. Impaired PGC-1{alpha} function in muscle in Huntington's disease Hum. Mol. Genet., August 15, 2009; 18(16): 3048 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Walter and F. Seebacher Endothermy in birds: underlying molecular mechanisms J. Exp. Biol., August 1, 2009; 212(15): 2328 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. You and C. Q. Rogers Adiponectin: A Key Adipokine in Alcoholic Fatty Liver Experimental Biology and Medicine, August 1, 2009; 234(8): 850 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Karamitri, A. M. Shore, K. Docherty, J. R. Speakman, and M. A. Lomax Combinatorial Transcription Factor Regulation of the Cyclic AMP-response Element on the Pgc-1{alpha} Promoter in White 3T3-L1 and Brown HIB-1B Preadipocytes J. Biol. Chem., July 31, 2009; 284(31): 20738 - 20752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-Céc. Durieux, G. D'Antona, D. Desplanches, D. Freyssenet, S. Klossner, R. Bottinelli, and M. Flück Focal adhesion kinase is a load-dependent governor of the slow contractile and oxidative muscle phenotype J. Physiol., July 15, 2009; 587(14): 3703 - 3717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garnier, J. Zoll, D. Fortin, B. N'Guessan, F. Lefebvre, B. Geny, B. Mettauer, V. Veksler, and R. Ventura-Clapier Control by Circulating Factors of Mitochondrial Function and Transcription Cascade in Heart Failure: A Role for Endothelin-1 and Angiotensin II Circ Heart Fail, July 1, 2009; 2(4): 342 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gao, J. Yin, J. Zhang, R. E. Ward, R. J. Martin, M. Lefevre, W. T. Cefalu, and J. Ye Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice Diabetes, July 1, 2009; 58(7): 1509 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mercader, J. Ribot, I. Murano, S. Feddersen, S. Cinti, L. Madsen, K. Kristiansen, M. L. Bonet, and A. Palou Haploinsufficiency of the retinoblastoma protein gene reduces diet-induced obesity, insulin resistance, and hepatosteatosis in mice Am J Physiol Endocrinol Metab, July 1, 2009; 297(1): E184 - E193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Adhihetty, G. Uguccioni, L. Leick, J. Hidalgo, H. Pilegaard, and D. A. Hood The role of PGC-1{alpha} on mitochondrial function and apoptotic susceptibility in muscle Am J Physiol Cell Physiol, July 1, 2009; 297(1): C217 - C225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Potthoff, T. Inagaki, S. Satapati, X. Ding, T. He, R. Goetz, M. Mohammadi, B. N. Finck, D. J. Mangelsdorf, S. A. Kliewer, et al. FGF21 induces PGC-1{alpha} and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response PNAS, June 30, 2009; 106(26): 10853 - 10858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lkhagvadorj, L. Qu, W. Cai, O. P. Couture, C. R. Barb, G. J. Hausman, D. Nettleton, L. L. Anderson, J. C. M. Dekkers, and C. K. Tuggle Microarray gene expression profiles of fasting induced changes in liver and adipose tissues of pigs expressing the melanocortin-4 receptor D298N variant Physiol Genomics, June 10, 2009; 38(1): 98 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Muraoka, A. Fukushima, S. Viengchareun, M. Lombes, F. Kishi, A. Miyauchi, M. Kanematsu, J. Doi, J. Kajimura, R. Nakai, et al. Involvement of SIK2/TORC2 signaling cascade in the regulation of insulin-induced PGC-1{alpha} and UCP-1 gene expression in brown adipocytes Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1430 - E1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Morton, L. Croft, J. D. Bartlett, D. P. M. MacLaren, T. Reilly, L. Evans, A. McArdle, and B. Drust Reduced carbohydrate availability does not modulate training-induced heat shock protein adaptations but does upregulate oxidative enzyme activity in human skeletal muscle J Appl Physiol, May 1, 2009; 106(5): 1513 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Gurd, Y. Yoshida, J. Lally, G. P. Holloway, and A. Bonen The deacetylase enzyme SIRT1 is not associated with oxidative capacity in rat heart and skeletal muscle and its overexpression reduces mitochondrial biogenesis J. Physiol., April 15, 2009; 587(8): 1817 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. DeFronzo From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus Diabetes, April 1, 2009; 58(4): 773 - 795. [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, H.-Z. Feng, D. Gupta, J. Kelleher, K. E. Dickerson, J. Wang, D. Hunt, W. Jou, O. Gavrilova, J.-P. Jin, et al. Gs{alpha} deficiency in skeletal muscle leads to reduced muscle mass, fiber-type switching, and glucose intolerance without insulin resistance or deficiency Am J Physiol Cell Physiol, April 1, 2009; 296(4): C930 - C940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Davis, E. A. Murphy, M. D. Carmichael, and B. Davis Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1071 - R1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qin, V. Haroutunian, P. Katsel, C. P. Cardozo, L. Ho, J. D. Buxbaum, and G. M. Pasinetti PGC-1{alpha} Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia Arch Neurol, March 1, 2009; 66(3): 352 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Delibegovic, D. Zimmer, C. Kauffman, K. Rak, E.-G. Hong, Y.-R. Cho, J. K. Kim, B. B. Kahn, B. G. Neel, and K. K. Bence Liver-Specific Deletion of Protein-Tyrosine Phosphatase 1B (PTP1B) Improves Metabolic Syndrome and Attenuates Diet-Induced Endoplasmic Reticulum Stress Diabetes, March 1, 2009; 58(3): 590 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Chisamore, H. A. Wilkinson, O. Flores, and J. D. Chen Estrogen-related receptor-{alpha} antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts Mol. Cancer Ther., March 1, 2009; 8(3): 672 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Palomer, D. Alvarez-Guardia, R. Rodriguez-Calvo, T. Coll, J. C. Laguna, M. M. Davidson, T. O. Chan, A. M. Feldman, and M. Vazquez-Carrera TNF-{alpha} reduces PGC-1{alpha} expression through NF-{kappa}B and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model Cardiovasc Res, March 1, 2009; 81(4): 703 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Neretti, P.-Y. Wang, A. S. Brodsky, H. H. Nyguyen, K. P. White, B. Rogina, and S. L. Helfand Long-lived Indy induces reduced mitochondrial reactive oxygen species production and oxidative damage PNAS, February 17, 2009; 106(7): 2277 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, C. E. Oropeza, K. H. Kaestner, and A. McLachlan Limited Effects of Fasting on Hepatitis B Virus (HBV) Biosynthesis in HBV Transgenic Mice J. Virol., February 15, 2009; 83(4): 1682 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Vercauteren, N. Gleyzer, and R. C. Scarpulla Short Hairpin RNA-mediated Silencing of PRC (PGC-1-related Coactivator) Results in a Severe Respiratory Chain Deficiency Associated with the Proliferation of Aberrant Mitochondria J. Biol. Chem., January 23, 2009; 284(4): 2307 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ranganathan, G. G. Harmison, K. Meyertholen, M. Pennuto, B. G. Burnett, and K. H. Fischbeck Mitochondrial abnormalities in spinal and bulbar muscular atrophy Hum. Mol. Genet., January 1, 2009; 18(1): 27 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation Physiol Rev, January 1, 2009; 89(1): 147 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Anderson, D. Shanmuganayagam, and R. Weindruch Caloric Restriction and Aging: Studies in Mice and Monkeys Toxicol Pathol, January 1, 2009; 37(1): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Arruda, L. A. Ketzer, M. Nigro, A. Galina, D. P. Carvalho, and L. de Meis Cold Tolerance in Hypothyroid Rabbits: Role of Skeletal Muscle Mitochondria and Sarcoplasmic Reticulum Ca2+ ATPase Isoform 1 Heat Production Endocrinology, December 1, 2008; 149(12): 6262 - 6271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Bombail, S. MacPherson, H. O.D. Critchley, and P. T.K. Saunders Estrogen receptor related beta is expressed in human endometrium throughout the normal menstrual cycle Hum. Reprod., December 1, 2008; 23(12): 2782 - 2790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hallberg, D. L. Morganstein, E. Kiskinis, K. Shah, A. Kralli, S. M. Dilworth, R. White, M. G. Parker, and M. Christian A Functional Interaction between RIP140 and PGC-1{alpha} Regulates the Expression of the Lipid Droplet Protein CIDEA Mol. Cell. Biol., November 15, 2008; 28(22): 6785 - 6795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Zhong and J. Xu Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1{alpha}: regulation by SUMOylation and oxidation Hum. Mol. Genet., November 1, 2008; 17(21): 3357 - 3367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Long and J. R. Zierath Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E545 - E552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Urschel and K. M. O'Brien High mitochondrial densities in the hearts of Antarctic icefishes are maintained by an increase in mitochondrial size rather than mitochondrial biogenesis J. Exp. Biol., August 15, 2008; 211(16): 2638 - 2646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Geier, I. V. Martin, C. G. Dietrich, N. Balasubramaniyan, S. Strauch, F. J. Suchy, C. Gartung, C. Trautwein, and M. Ananthanarayanan Hepatocyte nuclear factor-4{alpha} is a central transactivator of the mouse Ntcp gene Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G226 - G233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kus, T. Prazak, P. Brauner, M. Hensler, O. Kuda, P. Flachs, P. Janovska, D. Medrikova, M. Rossmeisl, Z. Jilkova, et al. Induction of muscle thermogenesis by high-fat diet in mice: association with obesity-resistance Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E356 - E367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lai, T. C. Leone, C. Zechner, P. J. Schaeffer, S. M. Kelly, D. P. Flanagan, D. M. Medeiros, A. Kovacs, and D. P. Kelly Transcriptional coactivators PGC-1{alpha} and PGC-l{beta} control overlapping programs required for perinatal maturation of the heart Genes & Dev., July 15, 2008; 22(14): 1948 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, A. Kovach, K. Suino-Powell, D. Martynowski, and H. E. Xu Structural and Biochemical Basis for the Binding Selectivity of Peroxisome Proliferator-activated Receptor {gamma} to PGC-1{alpha} J. Biol. Chem., July 4, 2008; 283(27): 19132 - 19139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Karnieli and M. Armoni Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E38 - E45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Jayasooriya, M. L. Mathai, L. L. Walker, D. P. Begg, D. A. Denton, D. Cameron-Smith, G. F. Egan, M. J. McKinley, P. D. Rodger, A. J. Sinclair, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance PNAS, May 6, 2008; 105(18): 6531 - 6536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Manmontri, M. Sariahmetoglu, J. Donkor, M. B. Khalil, M. Sundaram, Z. Yao, K. Reue, R. Lehner, and D. N. Brindley Glucocorticoids and cyclic AMP selectively increase hepatic lipin-1 expression, and insulin acts antagonistically J. Lipid Res., May 1, 2008; 49(5): 1056 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. R. LeMoine, C. E. Genge, and C. D. Moyes Role of the PGC-1 family in the metabolic adaptation of goldfish to diet and temperature J. Exp. Biol., May 1, 2008; 211(9): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rey, B. Sibille, C. Romestaing, M. Belouze, D. Letexier, S. Servais, H. Barre, C. Duchamp, and Y. Voituron Reptilian uncoupling protein: functionality and expression in sub-zero temperatures J. Exp. Biol., May 1, 2008; 211(9): 1456 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Xie, M. Chen, O. Gavrilova, E. W. Lai, J. Liu, and L. S. Weinstein Severe Obesity and Insulin Resistance due to Deletion of the Maternal Gs{alpha} Allele Is Reversed by Paternal Deletion of the Gs{alpha} Imprint Control Region Endocrinology, May 1, 2008; 149(5): 2443 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Nair, M. L. Bigelow, Y. W. Asmann, L. S. Chow, J. M. Coenen-Schimke, K. A. Klaus, Z.-K. Guo, R. Sreekumar, and B. A. Irving Asian Indians Have Enhanced Skeletal Muscle Mitochondrial Capacity to Produce ATP in Association With Severe Insulin Resistance Diabetes, May 1, 2008; 57(5): 1166 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Antonson, T. Jakobsson, T. Almlof, K. Guldevall, K. R. Steffensen, and J.-A. Gustafsson RAP250 Is a Coactivator in the Transforming Growth Factor {beta} Signaling Pathway That Interacts with Smad2 and Smad3 J. Biol. Chem., April 4, 2008; 283(14): 8995 - 9001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Szabadkai and M. R. Duchen Mitochondria: The Hub of Cellular Ca2+ Signaling Physiology, April 1, 2008; 23(2): 84 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Lavery, E. A. Walker, N. Turan, D. Rogoff, J. W. Ryder, J. M. Shelton, J. A. Richardson, F. Falciani, P. C. White, P. M. Stewart, et al. Deletion of Hexose-6-phosphate Dehydrogenase Activates the Unfolded Protein Response Pathway and Induces Skeletal Myopathy J. Biol. Chem., March 28, 2008; 283(13): 8453 - 8461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Garapaty, M. A. Mahajan, and H. H. Samuels Components of the CCR4-NOT Complex Function as Nuclear Hormone Receptor Coactivators via Association with the NRC-interacting Factor NIF-1 J. Biol. Chem., March 14, 2008; 283(11): 6806 - 6816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Civitarese and E. Ravussin Minireview: Mitochondrial Energetics and Insulin Resistance Endocrinology, March 1, 2008; 149(3): 950 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nakae, Y. Cao, M. Oki, Y. Orba, H. Sawa, H. Kiyonari, K. Iskandar, K. Suga, M. Lombes, and Y. Hayashi Forkhead Transcription Factor FoxO1 in Adipose Tissue Regulates Energy Storage and Expenditure Diabetes, March 1, 2008; 57(3): 563 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. De Filippis, G. Alvarez, R. Berria, K. Cusi, S. Everman, C. Meyer, and L. J. Mandarino Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E607 - E614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. de Wilde, R. Mohren, S. van den Berg, M. Boekschoten, K. W.-V. Dijk, P. de Groot, M. Muller, E. Mariman, and E. Smit Short-term high fat-feeding results in morphological and metabolic adaptations in the skeletal muscle of C57BL/6J mice Physiol Genomics, February 19, 2008; 32(3): 360 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Osabe, J. Sugatani, T. Fukuyama, S.-i. Ikushiro, A. Ikari, and M. Miwa Expression of Hepatic UDP-Glucuronosyltransferase 1A1 and 1A6 Correlated with Increased Expression of the Nuclear Constitutive Androstane Receptor and Peroxisome Proliferator-Activated Receptor {alpha} in Male Rats Fed a High-Fat and High-Sucrose Diet Drug Metab. Dispos., February 1, 2008; 36(2): 294 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Collier, J. L. Collier, R. P. Rhoads, and L. H. Baumgard Invited Review: Genes Involved in the Bovine Heat Stress Response J Dairy Sci, February 1, 2008; 91(2): 445 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barcelo-Batllori, S. G. Kalko, Y. Esteban, S. Moreno, M. C. Carmona, and R. Gomis Integration of DIGE and Bioinformatics Analyses Reveals a Role of the Antiobesity Agent Tungstate in Redox and Energy Homeostasis Pathways in Brown Adipose Tissue Mol. Cell. Proteomics, February 1, 2008; 7(2): 378 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Leick, J. F. P. Wojtaszewski, S. T. Johansen, K. Kiilerich, G. Comes, Y. Hellsten, J. Hidalgo, and H. Pilegaard PGC-1{alpha} is not mandatory for exercise- and training-induced adaptive gene responses in mouse skeletal muscle Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E463 - E474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, X. Shi, R. Padmanabhan, Q. Wang, Z. Wu, S. C. Stevenson, M. Hild, D. Garza, and H. Li Identification of novel modulators of mitochondrial function by a genome-wide RNAi screen in Drosophila melanogaster Genome Res., January 1, 2008; 18(1): 123 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Koulmann, L. Bahi, F. Ribera, H. Sanchez, B. Serrurier, R. Chapot, A. Peinnequin, R. Ventura-Clapier, and X. Bigard Thyroid hormone is required for the phenotype transitions induced by the pharmacological inhibition of calcineurin in adult soleus muscle of rats Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E69 - E77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Walter and F. Seebacher Molecular mechanisms underlying the development of endothermy in birds (Gallus gallus): a new role of PGC-1{alpha}? Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2007; 293(6): R2315 - R2322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ingwall On substrate selection for ATP synthesis in the failing human myocardium Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3225 - H3226. [Full Text] [PDF]
|
|
|
|
|
|
V. M. Diaz, S. Mori, E. Longobardi, G. Menendez, C. Ferrai, R. A. Keough, A. Bachi, and F. Blasi p160 Myb-Binding Protein Interacts with Prep1 and Inhibits Its Transcriptional Activity Mol. Cell. Biol., November 15, 2007; 27(22): 7981 - 7990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Pieter de Lange, M. Moreno, E. Silvestri, A. Lombardi, F. Goglia, and A. Lanni Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms FASEB J, November 1, 2007; 21(13): 3431 - 3441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Strand, Z. C. Baquet, A. K. Aragaki, P. Holmans, L. Yang, C. Cleren, M. F. Beal, L. Jones, C. Kooperberg, J. M. Olson, et al. Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration J. Neurosci., October 24, 2007; 27(43): 11758 - 11768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Li, Q. Kang, and D.-M. Wang Constitutive Coactivator of Peroxisome Proliferator-Activated Receptor (PPAR{gamma}), a Novel Coactivator of PPAR{gamma} that Promotes Adipogenesis Mol. Endocrinol., October 1, 2007; 21(10): 2320 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Q. Xiao, S. M. Williams, B. E. Grayson, M. M. Glavas, M. A. Cowley, M. S. Smith, and K. L. Grove Excess Weight Gain during the Early Postnatal Period Is Associated with Permanent Reprogramming of Brown Adipose Tissue Adaptive Thermogenesis Endocrinology, September 1, 2007; 148(9): 4150 - 4159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Dietrich, I. V. Martin, A. C. Porn, S. Voigt, C. Gartung, C. Trautwein, and A. Geier Fasting induces basolateral uptake transporters of the SLC family in the liver via HNF4{alpha} and PGC1{alpha} Am J Physiol Gastrointest Liver Physiol, September 1, 2007; 293(3): G585 - G590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Canto, S. Pich, J. C. Paz, R. Sanches, V. Martinez, M. Orpinell, M. Palacin, A. Zorzano, and A. Guma Neuregulins Increase Mitochondrial Oxidative Capacity and Insulin Sensitivity in Skeletal Muscle Cells Diabetes, September 1, 2007; 56(9): 2185 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sano, S. Tokudome, N. Shimizu, N. Yoshikawa, C. Ogawa, K. Shirakawa, J. Endo, T. Katayama, S. Yuasa, M. Ieda, et al. Intramolecular Control of Protein Stability, Subnuclear Compartmentalization, and Coactivator Function of Peroxisome Proliferator-activated Receptor {gamma} Coactivator 1{alpha} J. Biol. Chem., August 31, 2007; 282(35): 25970 - 25980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Karamanlidis, A. Karamitri, K. Docherty, D. G. Hazlerigg, and M. A. Lomax C/EBPbeta Reprograms White 3T3-L1 Preadipocytes to a Brown Adipocyte Pattern of Gene Expression J. Biol. Chem., August 24, 2007; 282(34): 24660 - 24669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schiaffino, M. Sandri, and M. Murgia Activity-Dependent Signaling Pathways Controlling Muscle Diversity and Plasticity Physiology, August 1, 2007; 22(4): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Remels, P. Schrauwen, R. Broekhuizen, J. Willems, S. Kersten, H. R. Gosker, and A. M. Schols Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD Eur. Respir. J., August 1, 2007; 30(2): 245 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yan, Z. Gao, G. Yu, Q. He, J. Weng, and J. Ye Nuclear Corepressor Is Required for Inhibition of Phosphoenolpyruvate Carboxykinase Expression by Tumor Necrosis Factor-{alpha} Mol. Endocrinol., July 1, 2007; 21(7): 1630 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Debevec, M. Christian, D. Morganstein, A. Seth, B. Herzog, M. Parker, and R. White Receptor Interacting Protein 140 Regulates Expression of Uncoupling Protein 1 in Adipocytes through Specific Peroxisome Proliferator Activated Receptor Isoforms and Estrogen-Related Receptor {alpha} Mol. Endocrinol., July 1, 2007; 21(7): 1581 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pirinen, T. Kuulasmaa, M. Pietila, S. Heikkinen, M. Tusa, P. Itkonen, S. Boman, J. Skommer, A. Virkamaki, E. Hohtola, et al. Enhanced Polyamine Catabolism Alters Homeostatic Control of White Adipose Tissue Mass, Energy Expenditure, and Glucose Metabolism Mol. Cell. Biol., July 1, 2007; 27(13): 4953 - 4967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Barash, M.-L. Bang, L. Mathew, M. L. Greaser, J. Chen, and R. L. Lieber Structural and regulatory roles of muscle ankyrin repeat protein family in skeletal muscle Am J Physiol Cell Physiol, July 1, 2007; 293(1): C218 - C227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Wright, P. C. Geiger, D.-H. Han, T. E. Jones, and J. O. Holloszy Calcium Induces Increases in Peroxisome Proliferator-activated Receptor {gamma} Coactivator-1{alpha} and Mitochondrial Biogenesis by a Pathway Leading to p38 Mitogen-activated Protein Kinase Activation J. Biol. Chem., June 29, 2007; 282(26): 18793 - 18799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dali-Youcef, C. Mataki, A. Coste, N. Messaddeq, S. Giroud, S. Blanc, C. Koehl, M.-F. Champy, P. Chambon, L. Fajas, et al. Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabesity because of increased energy expenditure PNAS, June 19, 2007; 104(25): 10703 - 10708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Crunkhorn, F. Dearie, C. Mantzoros, H. Gami, W. S. da Silva, D. Espinoza, R. Faucette, K. Barry, A. C. Bianco, and M. E. Patti Peroxisome Proliferator Activator Receptor {gamma} Coactivator-1 Expression Is Reduced in Obesity: POTENTIAL PATHOGENIC ROLE OF SATURATED FATTY ACIDS AND p38 MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION J. Biol. Chem., May 25, 2007; 282(21): 15439 - 15450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bogacka, T. W. Gettys, L. de Jonge, T. Nguyen, J. M. Smith, H. Xie, F. Greenway, and S. R. Smith The Effect of {beta}-Adrenergic and Peroxisome Proliferator-Activated Receptor-{gamma} Stimulation on Target Genes Related to Lipid Metabolism in Human Subcutaneous Adipose Tissue Diabetes Care, May 1, 2007; 30(5): 1179 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jell, S. Merali, M. L. Hensen, R. Mazurchuk, J. A. Spernyak, P. Diegelman, N. D. Kisiel, C. Barrero, K. K. Deeb, L. Alhonen, et al. Genetically Altered Expression of Spermidine/Spermine N1-Acetyltransferase Affects Fat Metabolism in Mice via Acetyl-CoA J. Biol. Chem., March 16, 2007; 282(11): 8404 - 8413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gershman, O. Puig, L. Hang, R. M. Peitzsch, M. Tatar, and R. S. Garofalo High-resolution dynamics of the transcriptional response to nutrition in Drosophila: a key role for dFOXO Physiol Genomics, March 14, 2007; 29(1): 24 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J Bailey Treating insulin resistance: future prospects Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 20 - 31. [Abstract] [PDF]
|
|
|
|
|
|
A. Sriwijitkamol, D. K. Coletta, E. Wajcberg, G. B. Balbontin, S. M. Reyna, J. Barrientes, P. A. Eagan, C. P. Jenkinson, E. Cersosimo, R. A. DeFronzo, et al. Effect of Acute Exercise on AMPK Signaling in Skeletal Muscle of Subjects With Type 2 Diabetes: A Time-Course and Dose-Response Study Diabetes, March 1, 2007; 56(3): 836 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Chow, L. J. Greenlund, Y. W. Asmann, K. R. Short, S. K. McCrady, J. A. Levine, and K. S. Nair Impact of endurance training on murine spontaneous activity, muscle mitochondrial DNA abundance, gene transcripts, and function J Appl Physiol, March 1, 2007; 102(3): 1078 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bonnelye, R. A. Zirngibl, P. Jurdic, and J. E. Aubin The Orphan Nuclear Estrogen Receptor-Related Receptor-{alpha} Regulates Cartilage Formation in Vitro: Implication of Sox9 Endocrinology, March 1, 2007; 148(3): 1195 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Olmsted-Davis, F. H. Gannon, M. Ozen, M. M. Ittmann, Z. Gugala, J. A. Hipp, K. M. Moran, C. M. Fouletier-Dilling, S. Schumara-Martin, R. W. Lindsey, et al. Hypoxic Adipocytes Pattern Early Heterotopic Bone Formation Am. J. Pathol., February 1, 2007; 170(2): 620 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Backhed, J. K. Manchester, C. F. Semenkovich, and J. I. Gordon From the Cover: Mechanisms underlying the resistance to diet-induced obesity in germ-free mice PNAS, January 16, 2007; 104(3): 979 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Finck The PPAR regulatory system in cardiac physiology and disease Cardiovasc Res, January 15, 2007; 73(2): 269 - 277. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
